Ticagrelor + Placebo
Phase 3Completed 1 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Acute Ischaemic Stroke
Conditions
Acute Ischaemic Stroke, Transient Ischaemic Attack
Trial Timeline
Jan 22, 2018 → Dec 13, 2019
NCT ID
NCT03354429About Ticagrelor + Placebo
Ticagrelor + Placebo is a phase 3 stage product being developed by AstraZeneca for Acute Ischaemic Stroke. The current trial status is completed. This product is registered under clinical trial identifier NCT03354429. Target conditions include Acute Ischaemic Stroke, Transient Ischaemic Attack.
What happened to similar drugs?
20 of 20 similar drugs in Acute Ischaemic Stroke were approved
Approved (20) Terminated (4) Active (0)
✅Modification of Prasugrel based on a biological assay + prasugrel / clopidogrelDaiichi SankyoApproved
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (9)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03615924 | Phase 3 | Terminated |
| NCT03354429 | Phase 3 | Completed |
| NCT02482298 | Phase 2 | Completed |
| NCT02352402 | Phase 3 | UNKNOWN |
| NCT02110303 | Phase 2/3 | Completed |
| NCT02335099 | Phase 1/2 | Completed |
| NCT01998399 | Phase 2 | Terminated |
| NCT02070653 | Phase 2 | Completed |
| NCT01347580 | Approved | Completed |
Competing Products
20 competing products in Acute Ischaemic Stroke